Chester County News and Community Website
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) announced it has completed the sale of its International Pharmaceuticals business, primarily operated through Canada-based Paladin Pharma Inc., to Knight Therapeutics Inc.
Endo, Inc. Finalizes $105M Sale of International Pharmaceuticals Business Read More DUBLIN, Ireland & MALVERN, PA — Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have detailed the senior leadership structure for their anticipated merger, a move aimed at creating a global …
Mallinckrodt and Endo Announce Leadership Plans for Transformative Merger Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has announced its Men’s Health Month initiative, reaffirming the company’s focus on improving awareness and resources for men’s health issues. Throughout June, the …
Endo, Inc. Launches Men’s Health Month Initiative to Raise Awareness Read More DUBLIN, Ireland & MALVERN, PA — Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have announced significant steps forward in their proposed merger aimed at creating a global leader in specialty …
Mallinckrodt and Endo Advance Key Milestones in Strategic Merger Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) announced its financial results for the first quarter ended March 31, 2025, highlighting solid growth in the Branded Pharmaceuticals segment and the reaffirmation …
Endo, Inc. Reports First-Quarter 2025 Financial Results Read More
QUAKERTOWN, PA — QNB Corp. (OTCQX: QNBC), the parent company of QNB Bank, has announced its transition to the OTCQX® Best Market from the Pink® market. The move represents a significant …
QNB Corp. Joins OTCQX Best Market Read More DUBLIN, IRELAND, AND MALVERN, PA — Pharmaceutical leaders Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have entered an agreement to merge, creating a global, diversified company poised to deliver enhanced patient …
Mallinckrodt and Endo Announce Merger to Build Diversified Pharmaceuticals Powerhouse Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for …
Endo, Inc. Shares Positive Data on XIAFLEX Treatment for Peyronie’s Disease Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has announced a definitive agreement to divest its International Pharmaceuticals business, operated primarily through Canada-based Paladin Pharma Inc., to Knight Therapeutics Inc. The deal, …
Endo, Inc. to Sell International Pharmaceuticals Business to Knight Therapeutics Read More